Drugs / RO7565020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05763576 | Apr 2023 → Dec 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7565020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05763576 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT05763576 ↗ |